Association Between Stroke and Adrenal Incidentalomas

If Adrenal Incidentalomas Have the Influences to Occur and Progress in Patients With Stroke

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05237817

Acronym

ABSAI

Enrollment

Registered

2022-02-14

Start date

2021-04-01

Completion date

2029-02-28

Last updated

2022-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Incidentaloma, Stroke

Keywords

Adrenal Incidentaloma, Autonomous cortisol secretion, Stroke

Brief summary

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

Detailed description

Background: Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke . The investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs. Objective: To measure the association between stroke and levels of autonomous cortisol secretion in patients with AIs. Design: Part 1, Retrospective cohort study. From April 1, 2021, to September 30, 2021, cohort patients with stroke were recruited in this study. The investigators assess the standardised incidence rate of AIs in all patients. Meanwhile, detail information about stroke disease、patient and AIs characteristics were record. Part 2, Prospective cohort study. From Mar 1, 2022, to Feb 29, 2024, cohort patients with stroke plane to recruit in this study. All patient receive the plasma cortisol level after a 1-mg dexamethasone suppression test. The investigators assess the standardised incidence rate of AIs in all patients. Meanwhile, detail information about stroke disease、patient and AIs characteristics would be record.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* stroke disease , such as Cerebral infarction、Intracerebral hemorrhage and Subarachnoid hemorrhage.

Exclusion criteria

* presence of metastatic cancer; * AIs smaller than 1 cm; * nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts; * oral glucocorticoid treatment with more than single doses in the past 3 months; * use of inhaled steroids or medication affecting dexamethasone metabolism; * systemic estrogen treatment.

Design outcomes

Primary

Measure	Time frame	Description
Plasma cortisol level	5 years	Plasma cortisol level after a 1-mg dexamethasone suppression test
Incidence rate of Adrenal incidentalomas	5 years	Assess the standardised incidence rate of AIs in all patients with stroke

Secondary

Measure	Time frame	Description
Diameter of Adrenal incidentalomas	5 years	Maximal axial diameter of adrenal incidentalomas by computed tomography scan; Millimetre as a metric unit of length in this study

Countries

China

Contacts

Primary ContactHao Yan, Dr.

yanhurology@qq.com+86-13651341058

Backup ContactTong W Ou, Dr.

outongwen@sohu.com

Outcome results